3 ETFs To Watch On Biotech Earnings

The earnings season is off to a flying start with equity markets scaling record highs, owing to a slew of upbeat economic data, strong corporate performance and President Donald Trump's tax reform proposal. However, the performance has been a mixed bag for biotech companies, with some beating market expectations, while a few failed to do so (read: U.S. Fiscal Deficit at 3.5% of GDP: ETFs in Focus).

We will now discuss the performance of a few biotech giants such as Amgen Inc AMGN, Gilead Sciences GILD, Biogen Inc BIIB and Alexion Pharmaceuticals ALXN (read: Should You Keep Your Portfolio Healthy with Biotech ETFs?).

Earnings in Focus

Amgen reported third-quarter 2017 adjusted earnings of $3.27 per share on Oct 25, 2017, surpassing the Zacks Consensus Estimate of $3.09 and increasing 8.3% from $3.02 per share in the year-ago quarter. The company also beat the Zacks Consensus Estimate on the revenue front. Amgen reported revenues of $5.773 billion, surpassing the Zacks Consensus Estimate of $5.743 billion but decreased 0.7% from $5.811 billion in the year-ago quarter.

The company updated its full-year non-GAAP EPS guidance to the range $10.96-$11.20 from the previous guided range of $10.79-$11.37, owing to hurricane-recovery costs. It also updated its revenue guidance to the range of $22.7-$23 billion from the previous guided range of $22.5-$23 billion. The company’s shares lost around 0.8% during after-hours trading on Oct 25, 2017, after it revised down its guidance.

Gilead Sciences reported third-quarter 2017 adjusted earnings of $2.06 per share on Oct 26, 2017, missing the Zacks Consensus Estimate of $2.09 and decreasing more than 25.1% from $2.75 per share in the year-ago quarter. However, the company beat the Zacks Consensus Estimate on the revenue front. The company reported revenues of $6.512 billion, surpassing the Zacks Consensus Estimate of $6.329 billion but decreased more than 13.2% from $7.500 billion in the year-ago quarter.

1 2 3
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any specific ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.